Enhancing Pfizer’s Position in Oncology

Pfizer continues to invest significant capital in the next generation of potential cancer breakthroughs, having announced its proposed acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio.

The companies expect to complete the transaction in late 2023 or early 2024, subject to fulfillment of customary closing conditions, including approval of Seagen’s stockholders and receipt of required regulatory approvals.

Once closed, Pfizer and Seagen will seek to accelerate the next generation of potential cancer treatment breakthroughs using innovative cancer-fighting technology.

Please see below for acquisition highlights and visit Pfizer’s Investor’s site for more information.

Pfizer and Seagen remain two separate, independent companies prior to closing. Closing of the transaction is subject to fulfillment of customary closing conditions, including receipt of required regulatory approvals and approval by a majority of Seagen’s outstanding common shares.

This forward-looking statements included herein involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. You should carefully consider the risks and uncertainties related to the proposed acquisition and the businesses of Pfizer and Seagen described in the press release dated March 13, 2023 announcing the proposed acquisition and their respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed by either of them from time to time with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Pfizer and Seagen assume no obligation to, and do not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. Neither Pfizer nor Seagen gives any assurance that it will achieve its expectations.

This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries.